Yi Chen, an analyst from H.C. Wainwright, has initiated a new Buy rating on VolitionRX (VNRX).
Yi Chen’s rating is based on VolitionRX’s innovative approach in the diagnostics field, particularly through their Nu.Q technology, which focuses on nucleosome-based diagnostics. The company’s successful commercialization of the Nu.Q Vet cancer test for dogs, available in over 20 countries, demonstrates the practical application and market acceptance of their technology. Furthermore, the potential for licensing agreements for human tests, such as Nu.Q NETs for sepsis and Nu.Q Cancer for various cancer-related diagnostics, indicates a promising growth trajectory.
Additionally, the recent commercial sale of the High Throughput Synthetic Sepsis method, which offers real-time monitoring of NETs activation and inhibition, showcases VolitionRX’s commitment to advancing medical diagnostics. The method’s ability to provide a more physiologically relevant environment for studying neutrophil responses and its potential clinical utility in risk stratification for sepsis patients further supports the company’s growth potential. These factors collectively contribute to Yi Chen’s Buy rating and the 12-month price target of $2.50 per share.
VNRX’s price has also changed dramatically for the past six months – from $0.772 to $0.460, which is a -40.41% drop .